Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor
US11820825B2 · kind B2 · utility
1Cited by
20References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2020 |
| Grant date | Nov 21, 2023 |
| Priority date | — |
| Expiry date | Oct 7, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.